ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2917 • 2013 ACR/ARHP Annual Meeting

    Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction

    Chris T. Derk1, Nora Sandorfi2, Shivani Purohit3 and Christopher Mecoli4, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, 3Rheumatology Division, Department of Medicine, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, 4Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Acute intestinal pseudo-obstruction is a rare gastrointestinal manifestation of SSc with little data existing as to the demographics, clinical course, outcomes and mortality of…
  • Abstract Number: 2895 • 2013 ACR/ARHP Annual Meeting

    Bacterial Amyloids Promote Type I Interferon Production and Accelerate Autoimmunity

    Paul Gallo, Glenn Rapsinski, Cagla Tukel and Stefania Gallucci, Dept. of Microbiology and Immunology, Laboratory of Dendritic Cell Biology, Temple Autoimmunity Center, Temple University School of Medicine, Philadelphia, PA

    Background/Purpose: Infection is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE).  This is largely due to the use of…
  • Abstract Number: 2878 • 2013 ACR/ARHP Annual Meeting

    The Importance Of Germinal Center-Like Structures In Primary Sjögren’s Syndrome Salivary Glands Beyond Lymphoma Risk

    Elke Theander1, Thomas Mandl2, Rolf Liedholm3, Roland Jonsson4, Malin V. Jonsson5 and Gunnar Warfvinge6, 1Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Dept of Rheumatology, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden, 3Department of oral and maxillofacial surgery, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, 4Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 5Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, 6Department of oral pathology, Skåne University Hospital Malmö, Lund University, Malmö, Sweden

    Background/Purpose: The association between germinal center (GC)-like structures and lymphoma in primary Sjögren's syndrome (pSS) has been demonstrated recently (1). Here we present a comprehensive…
  • Abstract Number: 2879 • 2013 ACR/ARHP Annual Meeting

    Prognostic Value Of Minor Salivary Gland Assessments In Primary Sjögren’s Syndrome

    Anna Risselada1, A.a. Kruize2, J.A.G. van Roon3, F.P.J.G. Lafeber4 and J.W.J. Bijlsma4, 1Clinical immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Salivary gland assessment is important for diagnosing primary Sjögren’s syndrome (pSS), as the lymphocytic focus score (LFS) is part of pSS classification criteria. Quantitative…
  • Abstract Number: 2880 • 2013 ACR/ARHP Annual Meeting

    Impact Of Different End Points On The Patient Cohort Size Needed To Demonstrate The Efficacy Of a Therapeutic Intervention In Pss. A Post Hoc Analysis Of The Tears Study (Tolerance and efficacy of Rituximab in primary Sjogren Syndrome study)

    Valerie devauchelle-Pensec1, Sandrine jousse-Joulin2, Xavier Mariette3, Jean-Marie Berthelot4, Aleth Perdriger5, Eric Hachulla6, Xavier Puechal7, Véronique le Guern8, Jean Sibilia9, Jacques-Eric Gottenberg10, Laurent Chiche Sr.11, Vincent Goeb12, Gilles Hayem13, Jacques Morel14, Charles Zarnitsky15, Jean Jacques Dubost16, Jacques-Olivier Pers17, Divi Cornec18, Raphaèle Seror19, Emmanuel Nowak20 and Alain Saraux21, 1Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, 2Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, 3Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 4Rheumatology Unit, Nantes University Hospital, Nantes, France, 5Rheumatology, Hôpital Sud, Rennes, France, 6Internal Medicine, Lille CEDEX, France, 7Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 8Department of Internal Medicine, Hôpital Cochin, Paris, France, 9Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 10Strasbourg University Hospital, Strasbourg, France, 11Internal Medicine, CHU Marseille, Marseille, France, 12Rheumatology, Amiens University Hospital, Amiens, France, 13Rheumatology Unit, Bichat Hospital, Paris, France, 14Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, 15Rheumatology, Le Havre General Hospital, Le Havre, France, 16Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, 17Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 18Department of rheumatology, Brest Occidentale University, Brest, France, 19Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, 20CIC, CHU Brest, Brest, France, 21Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France

    Background/Purpose: To calculate the sample sizes needed in future randomized controlled trials (RCTs) testing a therapeutic intervention in pSS, methodologists usually rely on data obtained…
  • Abstract Number: 2881 • 2013 ACR/ARHP Annual Meeting

    Ultrasonographic Salivary Glands Response To Rituximab In Primary Sjögren Syndrome Patients In the Tolerance and Efficacy Of Rituximab In Primary Sjogren Syndrome Study Is Not Associated With The Anatomopathology Changes

    Sandrine Jousse-Joulin1, Valerie Devauchelle-Pensec2, Divi Cornec3, Simon Gestin4, Luc Bressollette5, Thierry Marhadour6, Jacques-Olivier Pers7, Emmanuel Nowak8 and Alain Saraux9, 1Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, 2Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, 3Department of rheumatology, Brest Occidentale University, Brest, France, 4Vascular medicine, CHU Brest, Brest, France, 5Department of ultrasound, Brest Occidentale University, Brest, France, 6Rheumatology, CHU de la Cavale Blanche, Brest, France, 7Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 8CIC, CHU Brest, Brest, France, 9Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France

    Background/Purpose: We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Rituximab (RTX) in active pSS patients in France (TEARS study) and…
  • Abstract Number: 2882 • 2013 ACR/ARHP Annual Meeting

    B-Cell Depletion Modulates T-Helper Cell Balance In Patients With Primary Sjögren’s Syndrome

    WH Abdulahad1, FGM Kroese2, Gwenny Verstappen3, MG Huitema1, PM Meiners4, A Vissink5 and H Bootsma1, 1Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands, 3University of Groningen and University Medical Center Groningen, Groningen, Netherlands, 4Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 5Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: B-cell depletion therapy with a chimeric anti-human CD20 antibody (rituximab; RTX) is an effective treatment modality for patients with primary Sjögren’s syndrome (pSS). However,…
  • Abstract Number: 2883 • 2013 ACR/ARHP Annual Meeting

    Clinical Characteristics of Rheumatoid Arthritis Patients with Secondary Sjögren’s Syndrome and Association with Joint Damage

    Lindsay E. Brown1, Michelle A. Frits2, Christine K. Iannaccone2, Michael E. Weinblatt2, Nancy A. Shadick3 and Katherine P. Liao4, 1Internal Medicine, Massachusetts General Hospital, Boston, MA, 2Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Secondary Sjögren's syndrome (sSS) is a common extra-articular manifestation of rheumatoid arthritis (RA).  However, the clinical characteristics of this subgroup of patients are not…
  • Abstract Number: 2884 • 2013 ACR/ARHP Annual Meeting

    Prevalence Of Structural Lesions Seen On MRI-Spine In Patients With (Possible) Axial Spondyloarthritis (axSpA) Included In The SPACE-Cohort

    Manouk de Hooge1, Rosaline van den Berg2, Victoria Navarro-Compán2, Monique Reijnierse3, Floris van Gaalen2, Karen Fagerli4, Maureen C. Turina5, Maikel van Oosterhout6, Roberta Ramonda7, Tom Huizinga2 and Désirée van der Heijde8, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Radiology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 6Rheumatology, GHZ Hospital, Gouda, Netherlands, 7Rheumatology Unit, University of Padova, Padova, Italy, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Little is known about the prevalence of structural lesions (erosions, syndesmophytes, fatty lesions) on MRI of the spine (MRI-spine) in patients with chronic back…
  • Abstract Number: 2885 • 2013 ACR/ARHP Annual Meeting

    Erosions and Sclerosis, But Not Squaring, Predict The Development Of New Syndesmophytes: A 12-Year Longitudinal Analysis (OASIS)

    Sofia Ramiro1, A.M. van Tubergen2, Désirée van der Heijde3, Carmen Stolwijk4, Maxime Dougados5, Filip Van den Bosch6 and Robert Landewé7, 1Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 5Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 6Ghent University Hospital, Ghent, Belgium, 7Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands

    Background/Purpose: Erosions, sclerosis and squaring are included in the modified Stoke Ankylosing Spondylitis (AS) Spine Score (mSASSS). However, their value in predicting the development of…
  • Abstract Number: 2886 • 2013 ACR/ARHP Annual Meeting

    Prevalence Of Structural Lesions On MRI Of The Sacroiliac Joints In Patients With Early Axial Spondyloarthritis and Patients With Back Pain

    Rosaline van den Berg1, Manouk de Hooge1, Victoria Navarro-Compán1, Monique Reijnierse2, Floris van Gaalen1, Karen Fagerli3, Maureen Turina4, Maikel van Oosterhout5, Roberta Ramonda6, Tom Huizinga1 and Désirée van der Heijde1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Radiology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 5Rheumatology, GHZ Hospital, Gouda, Netherlands, 6Rheumatology Unit, University of Padova, Padova, Italy

    Background/Purpose: Little is known about the prevalence of structural lesions on MRI in the SI joints (MRI-SI) in recent onset axial spondyloarthritis (axSpA) patients and…
  • Abstract Number: 2887 • 2013 ACR/ARHP Annual Meeting

    The Spondyloarthritis Research Consortium Of Canada MRI Sacroiliac Joint Structural Score:  A Method For Reliable Detection Of Structural Progression

    Walter P. Maksymowych1, Stephanie Wichuk1, Praveena Chiowchanwisawakit2, Robert GW Lambert3 and Susanne Juhl Pedersen4, 1Medicine, University of Alberta, Edmonton, AB, Canada, 2Mahidol University, Bangkok, Thailand, 3Radiology, University of Alberta, Edmonton, AB, Canada, 4Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark

    Background/Purpose:   With increasing focus on effective treatment intervention in early spondyloarthritis, there is an unmet need for reliable assessment of structural progression in the…
  • Abstract Number: 2888 • 2013 ACR/ARHP Annual Meeting

    Frequent Detection Of Inflammation and Fat Infiltration Suggestive Of Spondyloarthritis On MRI Of The Entire Spine In Healthy Subjects and Patients With Mechanical Back Pain

    Ulrich Weber1, Zheng Zhao2, Veronika Zubler3, Stanley Chan4, Robert GW Lambert5, Mikkel Ostergaard6, Susanne Juhl Pedersen7, Kaspar Rufibach8 and Walter P. Maksymowych9, 1Rheumatology, Balgrist University Hospital, Zurich, Switzerland, 2Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, 3Radiology, Balgrist University Hospital, Zurich, Switzerland, 4Division of Ophthalmology, University of Alberta, Edmonton, AB, Canada, 5Radiology, University of Alberta, Edmonton, AB, Canada, 6Copenhagen Center for Arthritis Research, Glostrup, Denmark, 7Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 8rePROstat, Basel, Switzerland, 9Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Mechanical back pain (MBP) patients and healthy subjects may show spinal MRI lesions suggestive for spondyloarthritis (SpA) such as corner inflammatory lesions (CIL) or…
  • Abstract Number: 2889 • 2013 ACR/ARHP Annual Meeting

    Bone Marrow Edema and Structural Lesions In The Sacroiliac Joint In a Large Cohort Of Patients With Axial Spondyloarthritis, Chronic Low Back Pain and Healthy Controls

    L. van Hoeven1,2, J.J. Luime2, P.D.M. de Buck3, J.M.W. Hazes2 and A.E.a.M. Weel4, 1Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 2Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Rheumatology, MC Haaglanden, Den Haag, Netherlands, 4Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands

    Background/Purpose: MRI of the sacroiliac joint (SIJ) is included in the ASAS classification criteria for axial spondyloarthritis (axSpA) to identify patients at an earlier stage of…
  • Abstract Number: 2890 • 2013 ACR/ARHP Annual Meeting

    Novel Selective Inhibitors Of Nuclear Export (SINE) Decrease Type I Interferon Activation and Deplete Autoreactive Plasma Cells In The Kidney In Murine Lupus

    Teresa Owen1, Javier Rangel-Moreno2, Boris Klebanov3, Yosef Landesman3, Michael Kauffman3, Sharon Shacham3 and Jennifer H. Anolik4, 1Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, 3Karyopharm Therapeutics Inc., Natick, MA, 4Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose: There is great interest in developing new treatment approaches for SLE, but the biologic therapies under investigation over the past several years have yielded…
  • « Previous Page
  • 1
  • …
  • 2057
  • 2058
  • 2059
  • 2060
  • 2061
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology